Consequently, cytosolic β‐CATENIN levels increase, which then translocates to the nucleus, interacts with T‐cell factor and lymphoid enhancer factor (TCF/LEF), and activates transcription of target genes such as c‐MYC, CYCLIN D1 and SURVIVIN. 29, 30, 31, 32WNT/β‐CATENIN signalling is known to be activated in 50% of breast cancer patients,33 and promoter DNA hypermethylation of pathway antagonists such as APC, DKK3, SFRP1 and SFRP2 has been reported in many breast cancer samples.34, 35, 36. Here, SFRP1 is linked to breast carcinoma.